Hepatitis B, Aflatoxin B₁, and p53 Codon 249 Mutation in Hepatocellular Carcinomas from Guangxi, People’s Republic of China, and a Meta-analysis of Existing Studies

Marina C. Stern, David M. Umbach, Mimi C. Yu, Stephanie J. London, Zhen-Quan Zhang, and Jack A. Taylor

Laboratory of Molecular Carcinogenesis [M. C. S., J. A. T.], Epidemiology Branch [S. J. L., J. A. T.], and Biostatistics Branch [D. M. U.], National Institute of Environmental Health Sciences, NIH, Research Triangle Park, North Carolina 27709; Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California 90033 [M. C. Y.]; and Cancer Institute of Guangxi, Nanning, Guangxi 530021, People’s Republic of China [Z-Q. Z.]

Abstract
The incidence of hepatocellular carcinomas (HCC) varies widely worldwide, with some of the highest incidence rates found in China. Chronic infection with the hepatitis B virus (HBV) and exposure to aflatoxins in foodstuffs are the main risk factors. A G to T transversion at codon 249 of the p53 gene (249⁰⁰⁰) is commonly found in HCCs from patients in regions with dietary aflatoxin exposure. Because HBV infection is often endemic in high aflatoxin exposure areas, it is still unclear whether HBV acts as a confounder or as a synergistic partner in the development of HCC. Our report has two aims. First, we contribute data on HCCs from southern Guangxi, a high aflatoxin exposure area. Using DNA sequencing, we found that 36% (18 of 50) of tumors had a 249⁰⁰⁰ mutation. Also, 50% (30 of 60) were positive for p53 protein accumulation and 78% (28 of 36) were positive for HBV surface antigen, as detected by immunohistochemistry. Second, we present a meta-analysis, using our results along with those from 48 published studies, that examines the interrelationships among aflatoxin exposure, HBV infection, and p53 mutations in HCCs. We used a method that takes into account both within-study and study-to-study variability and found that the mean proportion of HCCs with the 249⁰⁰⁰ mutation was positively correlated with aflatoxin exposure (𝑃 = 0.0001). We found little evidence for an HBV-aflatoxin interaction modulating the presence of the p53 249⁰⁰⁰ mutation or any type of p53 mutation.

Introduction
The incidence of HCC varies widely worldwide. Among males, the highest incidence rates are found in eastern Asia, particularly in China where HCC is the third most common cause of cancer death (1). Chronic infection with the HBV is the strongest risk factor for HCC worldwide (2–4). However, populations with similar prevalence of HBV infection have different incidence of HCC (4), suggesting the presence of other important risk factors. Aflatoxins, a group of mycotoxins produced by the common fungi Aspergillus flavus and Aspergillus parasiticus, are established human hepatocarcinogens (5–9) and are well-known HCC risk factors when present in foodstuffs (3, 10).

The high-risk areas in eastern China include the Guangxi Autonomous Region. Fuzi County in southern Guangxi has a standardized rate of primary liver cancer among men of 120/100,000 population/year, a rate 35 times higher than that in the United States (3). HCC accounts for 50% of all of the cancer deaths in men and 25% of all of the cancer deaths in women in this region (11). A cohort study done in this area found a positive linear relationship for AF⁴ levels in foodstuffs and mortality attributable to HCC (3). The levels of AF⁴ were estimated to be as high as 2575 ng/kg/day (3), in contrast to the estimated 3 ng/kg/day exposure in the United States (12). Infection with HBV was significantly associated with HCC mortality, with 91% of HCC deaths occurring in HBV-positive subjects (3).

The tumor suppressor gene p53 is the most commonly mutated gene in human cancers (13). A G to T transversion at the third position of codon 249 of the p53 gene (249⁰⁰⁰) is commonly found in HCC from patients in regions with dietary aflatoxin exposure (14–24). In vitro studies (25–27) have supported this finding, showing that AF⁴ can induce this mutation. The biological activity of the 249⁰⁰⁰ mutant p53 protein remains undetermined. However, experiments (28) conducted with a murine p53 protein carrying the codon 249 homologous mutation (p53ser246) showed that the mutant protein could transform cells in culture and was defective in its transcription activation function. Studies done worldwide (reviewed in Refs. 29, 30) suggest that the frequency of the p53 249⁰⁰⁰ mutation in HCC correlates with the exposure level of AF⁴ in the underlying population. However, relatively few studies have been

Received 12/2000; revised 3/14/01; accepted 3/29/01.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 Partially supported by a National Cancer Institute Grant R35 CA53890 (to M. C. Y.).

2 To whom requests for reprints should be addressed, at National Institute of Environmental Health Sciences, P. O. Box 12233, MD A3-05, Research Triangle Park, NC 27709. Phone: (919) 541-4631; Fax: (919) 541-2511; E-mail: taylor@mehs.nih.gov.

3 The abbreviations used are: HCC, hepatocellular carcinoma; HBV, hepatitis B virus; AF⁴, aflatoxin B₁; HBsAg, HBV surface antigen; CI, confidence interval.
conducted in high aflatoxin exposure areas, and many have been small.

Some epidemiological (10, 24, 31, 32) and animal (33, 34) studies have found evidence for an HBV-aflatoxin interaction in hepatocarcinogenesis (reviewed in Ref. 30). Several mechanisms have been proposed to explain this interaction. The increase in cellular proliferation induced by HBV (35) could increase the proportion of cells in S phase that are susceptible to aflatoxin induced-p53 mutations. An increase in levels of aflatoxin metabolism enzymes (e.g., P450 enzymes) has been described for HBV transgenic mice and has been postulated as a mechanism for interaction (36). The HBVx protein, encoded by HBV, interferes with the nucleotide excision repair pathway (37), which cells use to repair aflatoxin-DNA adducts. Thus, the presence of the HBVx protein could increase the frequency of aflatoxin-induced mutations (37). Lastly, HBV infection could increase oxidative stress, which could lead to an increase in p53 mutations (38).

Epidemiological studies of the interrelationship among aflatoxin exposure, HBV status, and the presence of the p53 249ser mutation could help clarify whether HBV acts as a confounder or as a synergistic partner with aflatoxin. One study (24) in Taiwan found that, in the presence of aflatoxin, the p53 249ser mutation was significantly more frequent among HBV-positive than -negative subjects. Other studies found similar but not significant trends (18, 32, 39) or no differences at all (19, 21, 23, 40–46). The main limitation in investigating possible HBV-aflatoxin interaction is that in high exposure areas HBV infection is generally endemic, and few HBV-negative individuals are available for study.

Our report has two aims. First, we contribute additional data on p53 249ser mutation and HBV infection in HCC from southern Guangxi. This area has one of the highest aflatoxin exposure rates in the world and has provided valuable data establishing the role of aflatoxin and HBV in HCC (3, 11, 47), with the aflatoxin exposure level in the study area and with HBV infection status, analyzed all of the immunostained tumors. Where possible, non-neoplastic areas surrounding the tumors were also analyzed. For p53 staining, tumors were classified as positive or negative for the presence of nuclear staining above background. For HBV analysis, tumors were scored positive or negative for the presence of cytoplasmic staining.

Statistical Analysis. To examine possible associations between pairs of dichotomous outcomes, we analyzed 2 × 2 tables using Fisher’s exact test (48). Outcomes included the subject’s sex as well as the presence or absence of 249ser mutation, of p53 protein accumulation, and of detectable HBsAg. We compared mean age at cancer diagnosis among groups defined by combinations of outcome variables using ANOVA methods (48).

Meta-Analysis. We restricted our review to studies published in peer-reviewed journals before March 2000, plus the study presented here. To find studies, we searched Medline using search strings that used combinations of the words: p53 mutation, HCC, liver cancer, aflatoxin, HBV, or codon 249. We also looked at articles cited in those found via Medline.

Our goal was to analyze the proportion of tumors carrying p53 mutations and to see how those proportions changed with the aflatoxin exposure level in the study area and with HBV infection in the patient. To be included in our analysis, a study had to present the total number of tumors analyzed and individual information on p53 mutations obtained by direct DNA analysis. A number of studies, like our own, focused on 249ser mutations, either by RFLP or by direct sequencing, and did not screen for mutations in the rest of the gene. These studies are used in some analyses. To include a study in our analysis of all of the p53 mutations, we required it to have sequenced at least exons 4 through 8. HBV infection status was assessed in different studies using serum samples, tumors, or both by a variety of methods, including immunostaining, PCR to detect inte-
grated viral genome, ELISA, RIA, or Southern blots. In those studies where several techniques were used, we considered a subject positive if at least one technique showed positive results. To include a study in our analysis of whether HBV infection modified the effect of aflatoxin exposure on mutation frequency, we required cross-classified information on HBV infection and p53 mutation status. Finally, we required each study to provide sufficient information on the geographic origin of the tumor samples so that we could assess aflatoxin exposure. We classified study locations as having high, moderate, or low aflatoxin exposure based on work by Shen and Ong (29). They reviewed various studies and classified each according to either the quantity of aflatoxin in consumed food and/or determination of biomarkers (AFB1-DNA or protein adducts) in human tissue samples from each region using published information. We performed similar assessments for study locations that they did not classify.

We calculated several response variables for each study. These included the proportion of tumors that had any mutation in p53, the proportion of tumors that had a 249ser mutation, and the proportion of tumors with a 249ser mutation among those that had any p53 mutation. We also calculated the proportion of patients that had HBV infections among all of the patients. To examine possible HBV-aflatoxin interactions, we focused on the difference in the proportion of tumors with a given mutation between patients with HBV infection and those without it and looked at whether that difference might change with aflatoxin level. We also looked for interaction on the log odds ratio scale by applying a modified empirical logistic transformation (49) to the proportions and analyzing whether differences in the transformed proportions (i.e., empirical log odds ratios) changed with aflatoxin level. As a measure of interaction for this analysis, we preferred the difference in proportions to the empirical log odds ratios, primarily because with the latter measure observed proportions of zero must be excluded from the analysis, eliminating studies; e.g., if the observed proportions of 249ser mutations were zero in both HBV-positive and HBV-negative patients in a given study, we included that study in the analysis of differences in proportions (zero minus zero is zero) but not in the analysis on the log odds ratio scale (because zero divided by zero is indeterminate).

Each response variable was analyzed with a random effects model (50) incorporating study as a random effect and using aflatoxin exposure as a categorical covariate. We fitted these models using the MIXED procedure of Statistical Analysis System statistical software (SAS Institute, Inc., Cary, NC) following an approach outlined by Normand (51). This approach takes account of study-to-study heterogeneity in the underlying mean response that might arise, for example, from different populations under study or from different laboratory methods. The resulting estimates of mean response at each exposure level are weighted to take account of both within-study and study-to-study sources of variation and to accommodate the differing sample sizes in each study. When a proportion of zero or one is observed, the usual within-study estimate of the variance for such an observation is zero. Consequently, we examined the sensitivity of our conclusions to minor perturbations in within-study estimated variance. We also checked whether individual studies exerted undue influence on our conclusions by dropping one study at a time and reanalyzing the remainder.

Results

HCCs from Southern Guangxi. Patients ranged in age from 20 to 72 years. Most were males (77%). In 14 (22%) of the 64 samples, we were not able to obtain PCR products because of poor quality DNA. Of the remaining samples, we found that 18 (36%) had a G to T transversion at the third base of codon 249 of the p53 gene (249ser), whereas 32 (64%) were wild type. We observed no mutations in other codons of this small region of exon 7. For 22 (44%) of these samples, we performed independent DNA extractions and duplicate analysis to confirm the results and observed 100% concordance between these independent determinations. We found no differences in the frequency of 249ser mutation between females (33%) and males (37%; P = 1.00). Patients with 249ser mutation showed no statistically significant difference in mean age from those without the mutation (39 ± 8.3 versus 44 ± 13; P = 0.22).

Thirty samples (50%) showed accumulation of p53 protein in tumor cells. Four samples could not be analyzed. For the 48 samples with both DNA mutation and immunohistochemistry results, we saw concordance between protein accumulation and mutation in 30 samples, whereas 18 were nonconcordant. Among nonconcordant samples, three had 249ser mutation with no p53 protein accumulation, and 15 had wild-type codon 249 but positive immunohistochemistry. We found no statistically significant difference in the proportion of tumors with positive p53 staining between females (43%) and males (52%; P = 0.76). The mean age did not differ between patients positive (42 ± 13) and negative (42 ± 11) for p53 immunohistochemistry (P = 0.99).

For the analysis of HBV infection, we only included the 36 tumors that had non-neoplastic tissue available for staining because previous reports (52, 53) indicated that the majority of liver tumors tend to lose the HBV surface antigen, giving false-negative results. We excluded seven samples because poor tissue quality precluded their analysis. Twenty-eight tumors (78%) were positive for HBsAg, whereas eight (22%) were negative. Among the 28 positive tumors, 23 (82%) expressed the HBV antigen only in the non-neoplastic liver tissue, and 5 (18%) expressed it in both the neoplastic and non-neoplastic tissue. HBsAg status did not differ by gender (P = 1.00). Mean age at cancer diagnosis did not differ by HBsAg status (42 ± 11 versus 48 ± 15; P = 0.039).

Accumulation of p53 protein was detected in 17 (61%) of the 28 HBsAg-positive patients, compared with 2 (22%) of the 9 HBsAg-negative patients (P = 0.06). The 249ser mutation was found in 9 (36%) of the 25 HBsAg-positive patients, compared with 2 (40%) of the 5 HBsAg-negative patients (P = 1.00). Mean age at diagnosis did not differ among four groups of patients defined by cross-classifying HBsAg status with presence or absence of p53 accumulation in their tumors. Mean age at diagnosis did appear to differ, however, among four groups of patients defined by cross-classifying HBsAg status with codon 249 mutation status of their tumors (P = 0.07). In particular, HBsAg-positive patients whose tumors had the 249ser mutation had lower mean age at diagnosis than HBsAg-negative patients whose tumors had wild-type p53 (40 ± 6.8 versus 58 ± 1.5 years old, respectively).

Meta-Analysis. In all, 49 studies were available for meta-analysis (Table 1), 48 from the literature plus the current study, although not all of these studies contained data to address each question. We proceeded in two phases: we considered possible associations between p53 mutations and aflatoxin level ignoring HBV infection and, after that, we examined the role of HBV infection.
First, we investigated whether aflatoxin exposure level in a study area was associated with the proportion of tumors carrying any mutation in \(p53\) (Table 2).

The proportion of tumors carrying any mutation in \(p53\) showed a broad range across studies within each aflatoxin level: 45–69%, 13–50%, and 0–35% for high, moderate, and low levels, respectively. Our analysis showed that the mean proportion of tumors with some \(p53\) mutation changed with aflatoxin (\(P = 0.0001\)), with the highest weighted average in high aflatoxin areas (57%; Table 2). We saw a significant difference in mean frequency of \(p53\) mutations between high and moderate areas and between high and low areas.

Next, we looked at whether the proportion of tumors with a G to T mutation at the third position of \(p53\) codon 249 (249\(^{\text{ser}}\)) varied with aflatoxin exposure (Table 2). We found that these proportions exhibited variations within each afla-

---

**Table 1** Studies used for meta-analysis

<table>
<thead>
<tr>
<th>Location (reference)</th>
<th>High aflatoxin exposure regions</th>
<th>Moderate aflatoxin exposure regions</th>
<th>Low aflatoxin exposure regions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Guangxi, China (53)</td>
<td>na(^b)</td>
<td>na</td>
<td>na</td>
</tr>
<tr>
<td>Guangxi, China (current study)</td>
<td>18/50</td>
<td>28/38</td>
<td>8/24</td>
</tr>
<tr>
<td>Jiang-Su, China (41)</td>
<td>9/16</td>
<td>11/16</td>
<td>12/14</td>
</tr>
<tr>
<td>Mozambique (22)</td>
<td>8/15</td>
<td>15/15</td>
<td>8/15</td>
</tr>
<tr>
<td>Mozambique (42)</td>
<td>8/16</td>
<td>9/13</td>
<td>14/16</td>
</tr>
<tr>
<td>Mozambique (60)</td>
<td>5/6</td>
<td>na</td>
<td>7/7</td>
</tr>
<tr>
<td>Qidong, China (16)</td>
<td>8/16</td>
<td>8/16</td>
<td>7/7</td>
</tr>
<tr>
<td>Qidong, China (18)</td>
<td>21/35</td>
<td>34/36</td>
<td>21/33</td>
</tr>
<tr>
<td>Qidong, China (19)</td>
<td>9/20</td>
<td>16/20</td>
<td>8/16</td>
</tr>
<tr>
<td>Qidong, China (20)</td>
<td>13/25</td>
<td>15/25</td>
<td>13/25</td>
</tr>
<tr>
<td>Qidong, China (61)</td>
<td>7/14</td>
<td>7/14</td>
<td>7/14</td>
</tr>
<tr>
<td>Senegal (23)</td>
<td>10/15</td>
<td>na</td>
<td>8/13</td>
</tr>
<tr>
<td>Southern Africa (21)</td>
<td>3/10</td>
<td>5/10</td>
<td>8/9</td>
</tr>
<tr>
<td>Tongan, China (40)</td>
<td>7/21</td>
<td>na</td>
<td>13/16</td>
</tr>
<tr>
<td>Durban, South Africa (62)</td>
<td>2/24</td>
<td>na</td>
<td>na</td>
</tr>
<tr>
<td>Hong Kong, China (43)</td>
<td>2/26</td>
<td>6/26</td>
<td>28/31</td>
</tr>
<tr>
<td>Mexico (46)</td>
<td>3/16</td>
<td>na</td>
<td>11/20</td>
</tr>
<tr>
<td>Shanghai, China (19)</td>
<td>1/18</td>
<td>3/18</td>
<td>15/18</td>
</tr>
<tr>
<td>Shanghai, China (32)</td>
<td>10/52</td>
<td>na</td>
<td>37/48</td>
</tr>
<tr>
<td>Shanghai, China (44)</td>
<td>1/12</td>
<td>2/12</td>
<td>7/12</td>
</tr>
<tr>
<td>Shanghai, China (61)</td>
<td>3/10</td>
<td>5/10</td>
<td>10/10</td>
</tr>
<tr>
<td>Taiwan (24)</td>
<td>12/102</td>
<td>27/102</td>
<td>78/105</td>
</tr>
<tr>
<td>Taiwan (39)</td>
<td>4/61</td>
<td>20/61</td>
<td>41/61</td>
</tr>
<tr>
<td>Taiwan (63)</td>
<td>3/38</td>
<td>16/38</td>
<td>na</td>
</tr>
<tr>
<td>Taiwan (64)</td>
<td>0/13</td>
<td>3/13</td>
<td>17/20</td>
</tr>
<tr>
<td>Taiwan (65)</td>
<td>3/15</td>
<td>na</td>
<td>na</td>
</tr>
<tr>
<td>Thailand (45)</td>
<td>1/15</td>
<td>2/15</td>
<td>7/13</td>
</tr>
<tr>
<td>Transkei, South Africa (22)</td>
<td>1/12</td>
<td>1/12</td>
<td>0/0</td>
</tr>
<tr>
<td>Xian, China (44)</td>
<td>1/45</td>
<td>2/11</td>
<td>24/39</td>
</tr>
<tr>
<td>Alaska, United States (66)</td>
<td>0/13</td>
<td>0/13</td>
<td>12/14</td>
</tr>
<tr>
<td>Europe (67)</td>
<td>0/14</td>
<td>1/14</td>
<td>4/14</td>
</tr>
<tr>
<td>Europe (68)</td>
<td>1/19</td>
<td>6/19</td>
<td>7/22</td>
</tr>
<tr>
<td>Germany (69)</td>
<td>0/13</td>
<td>2/13</td>
<td>4/13</td>
</tr>
<tr>
<td>Germany (70)</td>
<td>0/20</td>
<td>2/20</td>
<td>4/20</td>
</tr>
<tr>
<td>Great Britain (71)</td>
<td>0/19</td>
<td>2/19</td>
<td>6/19</td>
</tr>
<tr>
<td>Italy (72)</td>
<td>0/20</td>
<td>6/20</td>
<td>12/20</td>
</tr>
<tr>
<td>Japan (73)</td>
<td>0/60</td>
<td>na</td>
<td>9/55</td>
</tr>
<tr>
<td>Japan (65)</td>
<td>0/6</td>
<td>na</td>
<td>na</td>
</tr>
<tr>
<td>Japan (74)</td>
<td>0/52</td>
<td>18/52</td>
<td>41/52</td>
</tr>
<tr>
<td>Japan (75)</td>
<td>0/43</td>
<td>7/43</td>
<td>na</td>
</tr>
<tr>
<td>Japan (76)</td>
<td>0/53</td>
<td>17/53</td>
<td>7/53</td>
</tr>
<tr>
<td>Japan (77)</td>
<td>0/20</td>
<td>3/20</td>
<td>8/20</td>
</tr>
<tr>
<td>Japan (78)</td>
<td>4/128</td>
<td>na</td>
<td>na</td>
</tr>
<tr>
<td>Japan (79)</td>
<td>3/34</td>
<td>10/34</td>
<td>na</td>
</tr>
<tr>
<td>Japan (80)</td>
<td>0/41</td>
<td>11/41</td>
<td>10/41</td>
</tr>
<tr>
<td>Northern China (41)</td>
<td>1/15</td>
<td>4/15</td>
<td>5/9</td>
</tr>
<tr>
<td>Singapore (81)</td>
<td>0/44</td>
<td>12/44</td>
<td>31/44</td>
</tr>
<tr>
<td>Singapore (52)</td>
<td>na</td>
<td>na</td>
<td>29/46</td>
</tr>
<tr>
<td>United States (82)</td>
<td>4/37</td>
<td>na</td>
<td>5/37</td>
</tr>
</tbody>
</table>

\(^a\) For the analysis of \(p53\) 249\(^{\text{ser}}\) mutation or any \(p53\) mutation and HBV status, we could only used tumors that had data for these two factors. Therefore, the total number of mutations within these analyses may not be the same as the total number of mutations observed when ignoring HBV status.

\(^b\) na, data not available.
toxin exposure level, ranging from 30–83%, 0–30%, and 0–11%, respectively (Fig. 1). The mean proportion of tumors having 249ser mutations changed with aflatoxin exposure ($P < 0.0001$) and was significantly larger in high aflatoxin areas (50%). Mean proportions did not differ significantly between the moderate (9%) and low (2%) aflatoxin areas.

The observed decrease in the proportion of 249ser mutations with decreasing aflatoxin exposure could reflect a general decrease in all of the $p53$ mutations or a decrease in this specific mutation alone. A comparison of mean proportions suggested that tumors with a 249ser mutation represented a majority of the tumors with $p53$ mutations in high aflatoxin areas but a minority in moderate or low aflatoxin areas. We examined this issue directly by analyzing the fraction of all of the tumors carrying $p53$ mutations that had a mutation in 249ser. The mean proportion of tumors with a 249ser mutation among tumors with any $p53$ mutation was strongly associated with level of aflatoxin exposure ($P < 0.0001$). At the high exposure level, on average 92% of tumors with $p53$ mutations were altered at codon 249 (Table 2). The corresponding mean proportions at the moderate and low exposure levels were 27% and 2%, respectively. All of

![Fig. 1](image_url)
the pairwise comparisons between aflatoxin levels were statistically significant. Thus, at higher aflatoxin levels, tumors with 249ser mutations represented a sharply increasing fraction of the tumors carrying p53 mutations.

The previous analyses indicate that the increase in p53 mutations with increasing aflatoxin exposure mainly reflects an increase in 249ser mutations. However, they do not indicate whether the frequency of mutations at p53 sites other than 249ser also change with aflatoxin exposure. To address this issue, we eliminated all of the tumors with 249ser mutations from the analysis (both numerator and denominator) and examined whether the proportion of p53 mutations in the remaining tumors changed with aflatoxin level (Table 2). We found evidence that aflatoxin exposure was associated with the proportion of tumors with non-249ser mutations, even after correcting for the frequency of 249ser mutations. Omission of any one of three studies from high exposure areas that found only 249ser mutations (i.e., estimated proportion of zero) rendered the association nonsignificant (P > 0.15), whereas omission of a single low exposure study that reported no non-249ser p53 mutations enhanced statistical significance. Consequently, in our view, how aflatoxin exposure may relate to the frequency of p53 mutations at sites other than codon 249 remains an open question.

The mean proportion of HBV-positive cases among all of the cases was associated with aflatoxin exposure level (P = 0.0001; Table 2). That proportion decreased from 91% in high exposure regions to 76% and 41% in moderate and low exposure regions, respectively.

We asked whether HBV infection modified the effect of aflatoxin exposure on the proportion of tumors with any mutation in the p53 gene (i.e., aflatoxin by HBV interaction). We examined this interaction by looking at whether the difference in the proportion of tumors with any p53 mutation between HBV-positive and HBV-negative tumors changed with aflatoxin exposure. The mean difference in the proportion of tumors that carried any p53 mutation appeared somewhat larger in the moderate exposure areas (18%) than in either the high (−1%) or the low exposure areas (−3%; Table 2; Fig. 2). However, the mean difference in proportions did not change significantly across aflatoxin levels (P = 0.15). Thus, the presence or absence of HBV infection did not appear to modulate the effect of aflatoxin exposure on the prevalence of liver tumors with p53 mutations. Moreover, the mean difference in proportions between HBV-positive and HBV-negative cases, averaged across aflatoxin levels, was only 5% (95% CI, −6–15%; P = 0.39), indicating little or no effect of HBV itself on the proportion of liver tumors carrying p53 mutations.

Lastly, we investigated whether HBV infection modified the effect of aflatoxin exposure on the proportion of tumors carrying a 249ser mutation. The mean difference in the proportion of tumors with a 249ser mutation between HBV-positive cases and HBV-negative cases was about the same at all of the aflatoxin levels (P = 0.70; Table 2). The mean difference in proportions between HBV-positive and HBV-negative cases, averaged across aflatoxin levels, was 6% (95% CI, −1–13%; P = 0.11), possibly suggesting a small effect of HBV infection on the proportion of liver tumors with a p53 249ser mutation.

Discussion
Accumulation of p53 protein is detectable by immunohistochemistry and is sometimes used as a surrogate for the presence of p53 mutations because the mutant protein has a longer half-life than the wild type. About half of our samples had accumulation of p53 protein, similar to previous reports from Guangxi (43%; Ref. 53) and Qidong, China (55% and 61%; Refs. 17, 54). However, our results do not support an earlier report that HCC patients with tumors that show p53 protein accumulation are younger than those without it (53).

In vitro experiments (55) have shown that the 249ser mutation may cause loss of tumor suppressor functions in hepatoma cell lines via loss of DNA-binding ability of the p53 protein. A similar finding was described using the mouse p53ser246 homologue mutation (28). Experiments with cells from transgenic mice expressing this mutant, under the control of the albumin promoter, have shown that the mutation promotes the transition of hepatocytes from G0 to G1 and/or M to G1. This result suggests a gain of function mutation (56). Interestingly, these transgenic mice had increased liver tumor development when exposed to AFB1 (57). Enhanced liver tumor development was reduced in mice that also expressed a wild-type p53, suggesting that loss of the wild-type allele may be required for the mutant to exert its effect (57). In our study from Guangxi, most tumors with the 249ser mutation did not have a corresponding wild-type allele, suggesting that there had been loss of heterozygosity, resulting in hemizygosity. This observation may support the hypothesis that 249ser mutations are recessive and do not have the dominant negative function reported for some other p53 mutations.

In vitro studies (27, 58) have shown that AFB1 can induce the 249ser mutation. These same studies also showed, however, that the 249ser mutation is not the only mutation induced in the p53 gene by AFB1, that this codon is not the preferred site for adduct formation, and that the removal of adducts at this site is
neither faster nor more efficient. These findings are not sufficient to explain why a 249<sup>ser</sup> mutation is more prevalent in high aflatoxin exposure areas.

Our meta-analysis indicates an association between the p53 249<sup>ser</sup> mutation and increasing levels of aflatoxin exposure. This association had been suggested previously by some of the population-based studies carried out in areas with different levels of aflatoxin exposure. However, given the variations in sample sizes, sample origin, and assessment of aflatoxin exposure from study to study, some uncertainty remained. One other meta-analysis (59) of 20 studies has investigated this question but was limited in that it used only two levels of aflatoxin exposure (low and high), included only two studies from high aflatoxin exposure areas, and used statistical methods that did not take into account the sample size of each study. Nonetheless, they also found that areas with high aflatoxin exposure levels were associated with a higher proportion of 249<sup>ser</sup> mutations in HCC that had p53 mutations.

Previous reports (18, 24, 32, 39) suggested that 249<sup>ser</sup> mutation is more common in HBV-positive tumors than in HBV-negative tumors. In the present study, we did not find strong evidence for such an association. The results of our meta-analysis found no clear evidence for an effect of HBV status on the frequency of any p53 mutation or aflatoxin-HBV interaction on p53 mutation frequency. We also did not find evidence for an aflatoxin-HBV interaction on 249<sup>ser</sup> mutation, but we did see some indication, not statistically significant, of a possible effect of HBV on the frequency of this mutation. One of the studies (24) we included in our meta-analysis tested for a possible HBV-aflatoxin interaction using odds ratios of prevalences. In our meta-analysis, we used differences in prevalences instead of odds ratios, as explained in “Materials and Methods.” When we used an empirical log odds approach (49) to reanalyze the studies in our meta-analysis, we found weak evidence for an HBV-aflatoxin interaction on 249<sup>ser</sup> mutations (P = 0.10) and significant evidence of an effect of HBV on the frequency of this mutation (P = 0.005). However, these results were strongly influenced by one study. Omitting it, we found no evidence for HBV-aflatoxin interaction (P = 0.57) and weak evidence for an HBV effect (P = 0.07). These results were similar to what we observed using differences in prevalences.

Our meta-analysis has some limitations that are worth discussing. In the majority of the studies, the aflatoxin exposure level was estimated as an ecological measure without using individual measurements of specific biomarkers. This approach may introduce a classification bias because individuals in each study area may vary in their levels of aflatoxin exposure. Regarding HBV exposure, the measurements in all of the studies were done at the individual level. However, two issues should be considered. On the one hand, different methods were used among studies to determine HBV infection status (see “Materials and Methods” for description). These different assays may detect different stages in the infection process that could influence the effect of HBV on p53 mutations. More specifically, some studies used methods that only detect the HBsAg, which can be absent in subjects that do express the HBV core antigen or that have the HBV-X gene integrated in their genome. In our meta-analysis, we did not control for this source of variability. On the other hand, as we showed in our own study in Guangxi, measurements of HBV infection using detection of HBsAg should be carefully done, avoiding the use of pure neoplastic tissue, because that may lead to false-negative results. A few studies included in our meta-analysis assessed HBV status by detecting HBsAg in tumors, and we could not determine whether they had taken this issue into account. Again, this fact might be a source of classification bias.

The results of almost 50 studies of p53 gene mutations in HCC demonstrate evidence of a dose-response relationship between ecological levels of AFB1 and prevalence of the p53 249<sup>ser</sup> mutation in primary HCC. Whether AFB1 causes these mutations or whether AFB<sub>1</sub> exposure leads to differential promotion of cells that acquired the mutation remains unclear. Although many population-based studies have provided evidence that HBV and aflatoxin can synergistically increase HCC risk, we find little evidence that this interaction also occurs at the molecular level in determining the frequency of p53 mutations.

Acknowledgments
We thank Julie F. Foley, Patricia S. Stockton, and Cindy R. Moorman from the Laboratory of Experimental Pathology, National Institute of Environmental Health Sciences, for their assistance in the processing, microdissection, and immunostaining of the samples. We also thank Drs. Robert Maronpot, Abraham Nyska, and Gordon P. Flake, also from the Laboratory of Experimental Pathology, National Institute of Environmental Health Sciences, for their assistance in the histopathological analysis of the tumors, Sue Edelstein from the Arts and Photography department for her assistance with graphics design, and Drs. Ruth M. Lunn and Dale P. Sandler for critical review of the manuscript.

References


26. Puisieux, A., Lim, S., Groopman, J., and Ozturk, M. Selective targeting of p53 gene mutational hotspots in human cancers by etiologically defined carcino-


28. Ghirmanious, N., Knoll, B. J., Wu, H., Lozano, G., and Sell, S. Character-

ization of a murine p53ser246 equivalent to the human p53ser249 assoc-


lar carcinoma is associated with genetic variation in the enzymatic detoxi-


Hepatitis B, Aflatoxin B₁, and p53 Codon 249 Mutation in Hepatocellular Carcinomas from Guangxi, People's Republic of China, and a Meta-analysis of Existing Studies


Updated version
Access the most recent version of this article at:
http://cebp.aacrjournals.org/content/10/6/617

Cited articles
This article cites 74 articles, 25 of which you can access for free at:
http://cebp.aacrjournals.org/content/10/6/617.full#ref-list-1

Citing articles
This article has been cited by 4 HighWire-hosted articles. Access the articles at:
http://cebp.aacrjournals.org/content/10/6/617.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link
http://cebp.aacrjournals.org/content/10/6/617.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.